| 产品描述: | SB-657510 是选择性的 urotensin II (UII) receptor (UT) 拮抗剂。 对于人,猴,猫,大鼠和小鼠的受体的 Ki 值分别为 61、17、30、65 和 56 nM。SB-657510 通过抑制 UII 诱导的人类血管内皮细胞中炎性介质,如粘附分子,细胞因子和组织因子上调发挥抗炎作用。 |
| 靶点: |
NeurotensinReceptor |
| 体外研究: |
SB-657510 dramatically blocks the UII-induced increase in adhesion between U937 and EA.hy926 cell. SB-657510 (1 μM; 0.5-8 hours) blocks the expression of tissue factor induced by UII in endothelial cells. SB-706375 (1-10000 nM) inhibits [Ca2+]i mobilization elicited by 10 nM hU-II with an IC50 of 180 nM. |
| 体内研究: |
SB-657510 inhibits the progression of high-fat diet induced atherosclerosis and diabetes-associated atherosclerosis. Levels of phosphorylated ERK are significantly attenuated in the aorta of SB-657510-treated (30 mg/kg/day) diabetic mice (Male Apoe KO mice). |
| 参考文献: |
1. Park SL, et al. Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Inducedby Urotensin II in Human Vascular Endothelial Cells. Biomol Ther (Seoul). 2013 Jul 30;21(4):277-83.
2. Behm DJ, et al. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol. 2008 Oct;155(3):374-86.
3. Watson AM, et al. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia. 2013 May;56(5):1155-65. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.976 ml |
9.881 ml |
19.763 ml |
| 5 mM |
0.395 ml |
1.976 ml |
3.953 ml |
| 10 mM |
0.198 ml |
0.988 ml |
1.976 ml |
| 50 mM |
0.04 ml |
0.198 ml |
0.395 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |